CSPC Innovation Pharma's Colorectal Cancer Drug Gets US FDA's Fast Track Designation; Shares Up 4%
MT Newswires Live
Aug 27
CSPC Innovation Pharmaceutical's (SHE:300765) first-in-class PD-1/IL-15 bispecific fusion protein, SYS6090 (JMT108), received a fast track designation from the U.S. Food and Drug Administration, according to a Wednesday disclosure on the Shenzhen bourse.
The Chinese pharmaceutical company's shares rose 4% during Thursday's afternoon trade.
The drug is developed by the company's subsidiary, CSPC Giant Biopharmaceutical, as a treatment for patients with microsatellite-stable or mismatch repair-proficient metastatic colorectal cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.